Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

@inproceedings{Lorente2016DeclineIC,
  title={Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer},
  author={David S{\'a}nchez Lorente and David R Olmos and Joaqu{\'i}n Mateo and Diletta Bianchini and George Seed and M. Fleisher and Daniel Costin Danila and Penny Flohr and Mateus Crespo and In{\^e}s Filipa Figueiredo and Susana Miranda and Kurt Baeten and Arturo Molina and Thian San Kheoh and Robert T McCormack and Leon W. M. M. Terstappen and Howard I. Scher and Johann S de Bono},
  booktitle={European urology},
  year={2016}
}
BACKGROUND Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of ≥5 cells/7.5ml are associated with poor CRPC outcome. OBJECTIVE To determine the value of a ≥30% CTC decline as a treatment response indicator. DESIGN, SETTING, AND PARTICIPANTS We identified patients with a baseline CTC count ≥5 cells/7.5ml and evaluable post-treatment CTC counts in two prospective trials… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 22 times over the past 90 days. VIEW TWEETS